Initial clinical assessment of a novel wound management system: a case series.

Alexander M. Reyzelman, Dean Vayser, S. William Tam, Cyaandi Dove

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The importance of exudate management for maintaining local moisture balance and avoiding maceration in the chronic wound environment is well established. The authors performed the initial clinical testing of a novel wound management system, Sepaderm (Aalnex, Inc, Irvine, California), designed to vertically wick and sequester excess exudate away from wound/periwound tissues to promote a healthy wound environment. In this series of 14 patients with lower-extremity chronic venous leg and diabetic foot ulcers, the 3-component system was well tolerated and demonstrated the ability to prevent exudate leakage onto periwound tissue and reduce existing pain and itching. All ulcers lasting 1.2 to 360 months were previously treated with standard therapies, including human cell-derived skin substitutes in some of the patients. After treatment with the new system for 7 to 174 days, 8 patients had various degrees of wound closure, ranging from 44% to 100%. The 6 patients who failed to show wound closure were treated with the new system for an average of 5.7 days, but demonstrated other clinical benefits. Future studies in larger patient populations with quantitative wound closure assessments, as well as measurements of exudate, periwound maceration, and pain management, are needed.

Original languageEnglish (US)
Pages (from-to)256-260
Number of pages5
JournalAdvances in skin & wound care
Issue number6
StatePublished - Jun 2011
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology
  • Advanced and Specialized Nursing


Dive into the research topics of 'Initial clinical assessment of a novel wound management system: a case series.'. Together they form a unique fingerprint.

Cite this